Recommencement of anticoagulation in chronic subdural haematoma: A systematic review and meta-analysis

Aswin Chari, Tiago Clemente Morgado, Daniele Rigamonti

Research output: Contribution to journalArticle

Abstract

Objective. Chronic subdural haematoma (CSDH) is becoming an increasingly important neurosurgical condition, especially given the aging world population and the increasing use of anticoagulant and antiplatelet medication. Clinicians regularly confront the dilemma of whether or not to restart anticoagulant and antiplatelet medication after CSDH, yet there is little evidence to support the decision-making process. This systematic review and meta-analysis aims to address this specific question. Methods. This systematic review and meta-analysis was conducted according to the PRISMA guidelines and has been registered with the PROSPERO international prospective register of systematic reviews (registration number CRD42012002509). Databases including MEDLINE, Cochrane, ISI Web of Knowledge, Embase and Google Scholar were searched for retrospective and prospective studies looking specifically at patients presenting with CSDH whilst on anticoagulant or antiplatelet medication which had data on subsequent recurrence and thromboembolic events. Results. Three relevant studies were found, totalling to 64 patients. In those restarted on anticoagulation, 11.1% experienced recurrences and 2.2% experienced thromboembolic events. In the control group that was not restarted on anticoagulation, 22.2% experienced recurrences and no patient experienced thromboembolic events. All recurrences and thromboembolic events occurred within the first 4 weeks of the initial surgical evacuation. Conclusions. The review seems to paradoxically suggest a lower bleeding risk and a higher thromboembolism risk when anticoagulation is restarted, although few concrete conclusions can be drawn from a pool of 64 patients. The decision on whether or not to restart anticoagulation in patients who present with CSDH whilst on anticoagulation has little empirical evidence to support a decision either way; more data are required to allow clinicians to make informed decisions about whether or not to restart anticoagulation, and if so, which drug, at what time-point and at what dose/therapeutic target.

Original languageEnglish (US)
Pages (from-to)2-7
Number of pages6
JournalBritish Journal of Neurosurgery
Volume28
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Hematoma, Subdural, Chronic
Meta-Analysis
Anticoagulants
Recurrence
Thromboembolism
MEDLINE
Decision Making
Retrospective Studies
Databases
Prospective Studies
Guidelines
Hemorrhage
Control Groups
Pharmaceutical Preparations
Population

Keywords

  • Anticoagulants
  • Chronic
  • Haematoma
  • Platelet aggregation inhibitors
  • Subdural

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Recommencement of anticoagulation in chronic subdural haematoma : A systematic review and meta-analysis. / Chari, Aswin; Clemente Morgado, Tiago; Rigamonti, Daniele.

In: British Journal of Neurosurgery, Vol. 28, No. 1, 01.2014, p. 2-7.

Research output: Contribution to journalArticle

@article{aa878a1efce84e75a4179e7b97111221,
title = "Recommencement of anticoagulation in chronic subdural haematoma: A systematic review and meta-analysis",
abstract = "Objective. Chronic subdural haematoma (CSDH) is becoming an increasingly important neurosurgical condition, especially given the aging world population and the increasing use of anticoagulant and antiplatelet medication. Clinicians regularly confront the dilemma of whether or not to restart anticoagulant and antiplatelet medication after CSDH, yet there is little evidence to support the decision-making process. This systematic review and meta-analysis aims to address this specific question. Methods. This systematic review and meta-analysis was conducted according to the PRISMA guidelines and has been registered with the PROSPERO international prospective register of systematic reviews (registration number CRD42012002509). Databases including MEDLINE, Cochrane, ISI Web of Knowledge, Embase and Google Scholar were searched for retrospective and prospective studies looking specifically at patients presenting with CSDH whilst on anticoagulant or antiplatelet medication which had data on subsequent recurrence and thromboembolic events. Results. Three relevant studies were found, totalling to 64 patients. In those restarted on anticoagulation, 11.1{\%} experienced recurrences and 2.2{\%} experienced thromboembolic events. In the control group that was not restarted on anticoagulation, 22.2{\%} experienced recurrences and no patient experienced thromboembolic events. All recurrences and thromboembolic events occurred within the first 4 weeks of the initial surgical evacuation. Conclusions. The review seems to paradoxically suggest a lower bleeding risk and a higher thromboembolism risk when anticoagulation is restarted, although few concrete conclusions can be drawn from a pool of 64 patients. The decision on whether or not to restart anticoagulation in patients who present with CSDH whilst on anticoagulation has little empirical evidence to support a decision either way; more data are required to allow clinicians to make informed decisions about whether or not to restart anticoagulation, and if so, which drug, at what time-point and at what dose/therapeutic target.",
keywords = "Anticoagulants, Chronic, Haematoma, Platelet aggregation inhibitors, Subdural",
author = "Aswin Chari and {Clemente Morgado}, Tiago and Daniele Rigamonti",
year = "2014",
month = "1",
doi = "10.3109/02688697.2013.812184",
language = "English (US)",
volume = "28",
pages = "2--7",
journal = "British Journal of Neurosurgery",
issn = "0268-8697",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Recommencement of anticoagulation in chronic subdural haematoma

T2 - A systematic review and meta-analysis

AU - Chari, Aswin

AU - Clemente Morgado, Tiago

AU - Rigamonti, Daniele

PY - 2014/1

Y1 - 2014/1

N2 - Objective. Chronic subdural haematoma (CSDH) is becoming an increasingly important neurosurgical condition, especially given the aging world population and the increasing use of anticoagulant and antiplatelet medication. Clinicians regularly confront the dilemma of whether or not to restart anticoagulant and antiplatelet medication after CSDH, yet there is little evidence to support the decision-making process. This systematic review and meta-analysis aims to address this specific question. Methods. This systematic review and meta-analysis was conducted according to the PRISMA guidelines and has been registered with the PROSPERO international prospective register of systematic reviews (registration number CRD42012002509). Databases including MEDLINE, Cochrane, ISI Web of Knowledge, Embase and Google Scholar were searched for retrospective and prospective studies looking specifically at patients presenting with CSDH whilst on anticoagulant or antiplatelet medication which had data on subsequent recurrence and thromboembolic events. Results. Three relevant studies were found, totalling to 64 patients. In those restarted on anticoagulation, 11.1% experienced recurrences and 2.2% experienced thromboembolic events. In the control group that was not restarted on anticoagulation, 22.2% experienced recurrences and no patient experienced thromboembolic events. All recurrences and thromboembolic events occurred within the first 4 weeks of the initial surgical evacuation. Conclusions. The review seems to paradoxically suggest a lower bleeding risk and a higher thromboembolism risk when anticoagulation is restarted, although few concrete conclusions can be drawn from a pool of 64 patients. The decision on whether or not to restart anticoagulation in patients who present with CSDH whilst on anticoagulation has little empirical evidence to support a decision either way; more data are required to allow clinicians to make informed decisions about whether or not to restart anticoagulation, and if so, which drug, at what time-point and at what dose/therapeutic target.

AB - Objective. Chronic subdural haematoma (CSDH) is becoming an increasingly important neurosurgical condition, especially given the aging world population and the increasing use of anticoagulant and antiplatelet medication. Clinicians regularly confront the dilemma of whether or not to restart anticoagulant and antiplatelet medication after CSDH, yet there is little evidence to support the decision-making process. This systematic review and meta-analysis aims to address this specific question. Methods. This systematic review and meta-analysis was conducted according to the PRISMA guidelines and has been registered with the PROSPERO international prospective register of systematic reviews (registration number CRD42012002509). Databases including MEDLINE, Cochrane, ISI Web of Knowledge, Embase and Google Scholar were searched for retrospective and prospective studies looking specifically at patients presenting with CSDH whilst on anticoagulant or antiplatelet medication which had data on subsequent recurrence and thromboembolic events. Results. Three relevant studies were found, totalling to 64 patients. In those restarted on anticoagulation, 11.1% experienced recurrences and 2.2% experienced thromboembolic events. In the control group that was not restarted on anticoagulation, 22.2% experienced recurrences and no patient experienced thromboembolic events. All recurrences and thromboembolic events occurred within the first 4 weeks of the initial surgical evacuation. Conclusions. The review seems to paradoxically suggest a lower bleeding risk and a higher thromboembolism risk when anticoagulation is restarted, although few concrete conclusions can be drawn from a pool of 64 patients. The decision on whether or not to restart anticoagulation in patients who present with CSDH whilst on anticoagulation has little empirical evidence to support a decision either way; more data are required to allow clinicians to make informed decisions about whether or not to restart anticoagulation, and if so, which drug, at what time-point and at what dose/therapeutic target.

KW - Anticoagulants

KW - Chronic

KW - Haematoma

KW - Platelet aggregation inhibitors

KW - Subdural

UR - http://www.scopus.com/inward/record.url?scp=84893072527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893072527&partnerID=8YFLogxK

U2 - 10.3109/02688697.2013.812184

DO - 10.3109/02688697.2013.812184

M3 - Article

C2 - 23834661

AN - SCOPUS:84893072527

VL - 28

SP - 2

EP - 7

JO - British Journal of Neurosurgery

JF - British Journal of Neurosurgery

SN - 0268-8697

IS - 1

ER -